Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen T Coffman

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Molecular Cancer Therapeutics|August 13, 2009
Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinibChing Ching Leow, Jon Chesebrough, Karen T Coffman, et al.
Cancer Research|November 25, 2003
Differential EphA2 epitope display on normal versus malignant cellsKaren T Coffman, Min Hu, Kelly Carles-Kinch, et al.
Molecular Cancer Therapeutics|February 18, 2003
Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancerSulma I Mohammed, Bruce A Craig, Anthony J Mutsaers, et al.
Neoplasia (New York, N.Y.)|June 2, 2009
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumorsElizabeth M Bruckheimer, Christine A Fazenbaker, Sandra Gallagher, et al.
JCI Insight|February 8, 2022
Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLCEric Tu, Kelly McGlinchey, Jixin Wang, et al.
Journal of the National Cancer Institute|November 2, 2006
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancerCharles N Landen, Chunhua Lu, Liz Y Han, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Molecular Cancer Therapeutics|August 13, 2009
Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinibChing Ching Leow, Jon Chesebrough, Karen T Coffman, et al.
Cancer Research|November 25, 2003
Differential EphA2 epitope display on normal versus malignant cellsKaren T Coffman, Min Hu, Kelly Carles-Kinch, et al.
Molecular Cancer Therapeutics|February 18, 2003
Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancerSulma I Mohammed, Bruce A Craig, Anthony J Mutsaers, et al.
Neoplasia (New York, N.Y.)|June 2, 2009
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumorsElizabeth M Bruckheimer, Christine A Fazenbaker, Sandra Gallagher, et al.
JCI Insight|February 8, 2022
Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLCEric Tu, Kelly McGlinchey, Jixin Wang, et al.
Journal of the National Cancer Institute|November 2, 2006
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancerCharles N Landen, Chunhua Lu, Liz Y Han, et al.
Pageof 1